| Title: | Lipoprotein(a), Insulin Resistance, and Cardiovascular Disease in the UK Biobank |
| Journal: | Journal of the American Heart Association |
| Published: | 11 Feb 2026 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/41669947/ |
| DOI: | https://doi.org/10.1161/jaha.125.042361 |
Publication 18307
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
BACKGROUND: Insulin resistance (IR) and lipoprotein(a), Lp(a), are established contributors to cardiovascular disease (CVD) risk. Whether IR modifies the association between Lp(a) and CVD in primary prevention remains uncertain.</p>
METHODS: This prospective cohort study included UK Biobank participants without baseline CVD. IR at enrollment was assessed using the triglyceride-glucose index (TyG). The primary outcome was first major adverse cardiovascular event, defined as peripheral arterial disease, coronary artery disease, myocardial infarction, ischemic stroke, or cardiovascular death. Cox models estimated adjusted hazard ratios (aHRs) with 95% CIs for log-transformed Lp(a) and TyG, adjusting for each other. Lp(a) was categorized as <125 or ≥125 nmol/L; high IR was TyG ≥75th cohort percentile. Participants were stratified into 4 joint Lp(a)/IR groups using low Lp(a)/low IR as reference.</p>
RESULTS: Among 328 031 participants (mean age 56.4 years; 54.7% women), 26 865 CVD events occurred over 14.6 years median follow-up (interquartile range 13.7-15.4). Per 1-SD increase, aHRs were 1.08 (95% CI, 1.06-1.09) for log-Lp(a) and 1.06 (95% CI, 1.04-1.07) for TyG, each adjusted for the other. The P-value for the multiplicative interaction between TyG and Lp(a) was 0.07. Relative to reference, aHRs (95% CI) were 1.15 (1.10-1.20) for ≥125/low IR, 1.09 (1.06-1.12) for <125/high IR, and 1.32 (1.24-1.41) for ≥125/high IR.</p>
CONCLUSIONS: Lp(a) and IR each independently contribute to cardiovascular risk, with a combination offering improved risk stratification. This suggests that accounting for IR may enhance the assessment of Lp(a)-associated risk in the context of primary CVD prevention setting.</p>
17 Keywords
- Aged
- Biological Specimen Banks
- Biomarkers
- Blood Glucose
- Cardiovascular Diseases
- Female
- Humans
- Insulin Resistance
- Lipoprotein(a)
- Male
- Middle Aged
- Prospective Studies
- Risk Assessment
- Risk Factors
- Triglycerides
- UK Biobank
- United Kingdom
13 Authors
- Richard Kazibwe
- Christopher L. Schaich
- Parag A. Chevli
- Jeff A. Kingsley
- Saeid Mirzai
- Juliana H. Namutebi
- Muhammad Imtiaz Ahmad
- Anurag Mehta
- Harpreet S. Bhatia
- Mitchell Paukner
- Rishi Rikhi
- Erin D. Michos
- Michael D. Shapiro
1 Application
| Application ID | Title |
|---|---|
| 97439 | Association of emerging cardiovascular disease biomarkers and markers of metabolic health with subclinical atherosclerosis, clinical atherosclerotic cardiovascular disease, and mortality |
Enabling scientific discoveries that improve human health